Article
Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment.
The Journal of clinical endocrinology and metabolism - 1 Aug 2001
Ballarè E, Persani L, Lania A G, Filopanti M, Giammona E, Corbetta S, Mantovani S, Arosio M, Beck-Peccoz P, Faglia G, Spada A
Abstract excerpt
Introduction of somatostatin analogs has greatly contributed to improving the prognosis of acromegaly. Although the majority of patients are effectively treated by these agents, resistance occurs in a subset of patients. So far, resistance to somatostatin has never been associated with mutations of the somatostatin receptor subtypes (sst2 and sst5) that inhibit GH secretion. Molecular analysis of genomic DNA from...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.